BioWorld

April 23, 2010

View Archived Issues

Transient Receptor Potential Channels Keep Branching Out

Read More

Aragon Raises $22M to Move 2 Cancer Drugs Into the Clinic

Read More

Earnings Roundup

Read More

Stock Movers

Read More

Clinic Roundup

Read More

Other News To Note

Read More

After Mixed Phase III, Alimera Prices $72M IPO Below Range

Four months after delivering mixed Phase III data on diabetic macular edema drug Iluvien, Alimera Sciences Inc. raised $72.1 million in its initial public offering. (BioWorld Today) Read More

Amgen Boasts Solid Quarter; Prolia Launch on the Horizon

Read More